Absci initiates ind-enabling studies for abs-101, a potential best-in-class anti-tl1a antibody de novo designed and optimized using generative ai

Ind submission expected in q1 2025; phase 1 trials anticipated to initiate shortly after ind submission expected in q1 2025; phase 1 trials anticipated to initiate shortly after
ABSI Ratings Summary
ABSI Quant Ranking